1.0 Introduction

This Clinical Practice Guideline (CPG) refers to the therapeutic plasma exchange for an infant /child with evidence of Antibody Mediated Rejection (AMR) after heart transplant. The goal of TPE is to remove donor-specific antibodies and/or inflammatory mediators implicated in AMR. The number of therapeutic plasma exchanges is patient specific and is ordered by the physician responsible for the patient's care. Please see Therapeutic Plasma Exchange under related documents for CPG on procedure.

The target users of this guideline will be Nurses, Physicians within the Nephrology and Cardiology programs.

Indications: This CPG applies to infants/children who have evidence of AMR.

Contraindications: Plasma exchanges should not ordinarily be performed within 24 hours of an operative procedure. If necessary to bypass this recommendation, the Staff M.D. must document the need for the procedure in the patient chart.

2.0 Definitions

- **Fresh Frozen Plasma (FFP)** - is separated from whole blood and is frozen within eight hours of collection. FFP contains all the coagulation factors in normal concentrations. Plasma is free of red blood cells, leukocytes and platelets. Plasma also has volume expansion and oncotic properties.

- **Total Blood Volume (TBV)** - the amount of blood in the whole body, both cells and fluid. The volume of the patient's blood is based on the patient's weight. The TBV is related to lean body mass. There is a difference between children and adults with newborns having a higher TBV per kg because of their higher packed red cell volume. TBV is calculated using the following formula:

  - Neonates (0-1 month): 100 ml/kg
  - Infants/children (1month-16 years) 80 ml/kg
  - Adolescents (16 years and older) 70 ml/kg

- **Plasma Volume** is the total volume of plasma in the body.

  - Plasma Volume = TBV (ml) X (1-hematocrit)

- **Exchange** - patient plasma is replaced by donor plasma. The exchange product can be either FFP, 5% Albumin or a combination of both.
3.0 Clinical Recommendations

**Version**

**Heart Transplant - Antibody Mediated Rejection Therapeutic Plasma Exchange**

**Pre-exchange requirements**

1. All recently post-transplant patients should be connected to cardiac monitor during plasma exchange
2. Complete following blood work 12-24h prior to the procedure:
   - CBC and Differential
   - INR, PTT
   - Albumin
   - K, Mg, Ca, Na
   - TCO2
3. Ensure blood work is within acceptable range
4. Complete the following blood work after the procedure:
   - INR, PTT
   - K, Mg, Ca, Na
   - TCO2

**Order replacement solution**

Replacement solution must be compatible with the patient's serum blood type and the donor blood type. Refer to Blood Group Chart for donor blood products compatible with recipient.

**Blood prime**

- Prussian Blue
- 5% Albumin
- 5% Dextrose

**Medications**

- Refer to NDD norms for specific medications
- Additional medications to increase risk of a reaction to either blood or blood product include:

- Hydrocortisone (25mg IM) if patient presents with anaphylaxis when blood prime and/or FFP present (maximum dose: 50mg)
- Calcium Gluconate

**Volume and number of exchanges**

1. Recommended volume of exchange is 1-1.5 times Plasma Volume
2. Procedure to be performed daily for 5 days, then reassessed
3. Improvement in cardiac function, biopsy findings, and donor-specific antibody levels are used to determine timing of discontinuation

**Measurement responses**

- Of incompatible heart transplant decreased washout time in times
- HLA specific rejection with donor-specific antibodies OR non-specific antibody-mediated rejection: stabilization or improvement in allograft function

**Acceptable blood work values prior to exchange:**

- MCH = 30 g/L
- GFR = 1.0 mg/dL
- PLT = 100-400,000
- INR = 1.5
- TCO2 = 25-30 mmol/L
- K = 4.0-5.0 mmol/L
- Mg = 0.8-1.0 mmol/L
- Ca = 2.2-2.6 mmol/L

**Related Documents:**

Therapeutic Plasma Exchange Procedure
Management of Citrate Toxicity
Blood component Infusions

©The Hospital for Sick Children ("SickKids"). All Rights Reserved. This document was developed solely for use at SickKids. SickKids accepts no responsibility for use of this material by any person or organization not associated with SickKids. A printed copy of this document may not reflect the current, electronic version on the SickKids Intranet. Use of this document in any setting must be subject to the professional judgment of the user. No part of the document should be used for publication without prior written consent of SickKids.
5.0 References

1. McLeod, B C Apheresis: Principles and Practice. 1997 (409-415)

Attachments:

Heart Transplant_care pathway_Feb 2022 (1).pdf